Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 149, Issue -, Pages 95-106Publisher
ELSEVIER
DOI: 10.1016/j.addr.2019.08.005
Keywords
Sequential release; Angiogenesis; Hydrogel carriers; Growth factors
Categories
Funding
- Maryland Stem Cell Fund [MSCRFF-3928]
- NCI Physical Sciences-Oncology Center [U54CA210173]
- Maryland Stem Cells Research Fund [MSCRFI-2784]
- American Heart Association [15EIA22530000]
Ask authors/readers for more resources
In recent years, as the mechanisms of vasculogenesis and angiogenesis have been uncovered, the functions of various pro-angiogenic growth factors (GFs) and cytokines have been identified. Therefore, therapeutic angiogenesis, by delivery of GFs, has been sought as a treatment for many vascular diseases. However, direct injection of these protein drugs has proven to have limited clinical success due to their short half-lives and systemic off-target effects. To overcome this, hydrogel carriers have been developed to conjugate single or multiple GFs with controllable, sustained, and localized delivery. However, these attempts have failed to account for the temporal complexity of natural angiogenic pathways, resulting in limited therapeutic effects. Recently, the emerging ideas of optimal sequential delivery of multiple GFs have been suggested to better mimic the biological processes and to enhance therapeutic angiogenesis. Incorporating sequential release into drug delivery platforms will likely promote the formation of neovasculature and generate vast therapeutic potential. (C) 2019 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available